New hope for older AML patients: drug combo trial launches
NCT ID NCT03513484
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 22 times
Summary
This study tests a combination of two drugs, nintedanib and azacitidine, in older adults with a type of acute myeloid leukemia (AML) that has certain genetic features. Participants are not candidates for or have declined standard intensive chemotherapy. The goal is to find the safest dose of nintedanib when given with azacitidine and to monitor side effects. Treatment continues for up to 6 cycles, with possible maintenance, unless the leukemia worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.